Th17 cells and IL-17 also play a critical role in the microenvironment of bone marrow in MM patients, as they not only stimulate the growth of myeloma cells, but also break the normal bone balance and accelerate bone destruction by stimulating osteoclasts and inhibiting osteoblasts [11, 12]. This evidence concerns the gene IL17A and Miyoshi myopathy.